Unlike non-tumor-bearing mice, there was no significant alteration in the levels of IL17A and IL17E between the two groups of tumor-bearing mice, but there was a significant increase in IL17A/F, heterodimer of IL17A and IL17F, which are known to work in concert to enhance breast cancer aggressiveness (Figure 5). This evidence concerns the gene IL17A and breast cancer.